Skip to main content
Hengrui Pharma logo

Hengrui Pharma — Investor Relations & Filings

Ticker · 600276 ISIN · CNE0000014W7 LEI · 2549003BT1XS3SE3E448 HKEX Manufacturing
Open in API
Filings indexed 2,705 across all filing types
Latest filing 2026-04-14 Transaction in Own Shar…
Country CN China
Listing HKEX 600276

About Hengrui Pharma

https://www.hrs.com

Hengrui Pharma is an innovative, global pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines. The company specializes in therapies for oncology, surgical applications, and interventional imaging. With a strong commitment to R&D, Hengrui has developed and commercialized numerous new molecular entities and is expanding its portfolio to address unmet medical needs in international markets. Its core activities revolve around creating high-quality and accessible treatments, particularly in the field of cancer therapy.

Recent filings

Filing Released Lang Actions
H股公告-翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a detailed HKEX ‘‘翌日披露報表’’ (Next-day Disclosure Form) reporting movements in issued and treasury shares, including share repurchases by the issuer for its employee share plan, in compliance with Listing Rules 13.25A/17.27A etc. It provides breakdowns of repurchased shares, dates, prices, and confirms board authorizations. This is not an earnings release, annual report or management discussion, but a mandated share buy-back/treasury shares transaction disclosure. Hence it classifies as a Transaction in Own Shares (POS).
2026-04-14 Chinese
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules, detailing share repurchases (treasury share transactions) by the issuer, including opening/closing balances, repurchase dates, prices, and confirmatory statements. This is a direct report of the company buying back its own shares, matching the definition of ‘Transaction in Own Shares’ (Code POS).
2026-04-14 English
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Hengrui Medicine Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug name, approval for clinical trials, and related risk disclosures. The document is short (823 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug trial approval and does not fit other specific categories.
2026-04-10 Chinese
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 88% confidence The document is extremely brief (242 characters) and simply states that an announcement has been published elsewhere on the issuer’s site. It does not contain substantive report content, financial data, or detailed disclosures. This matches the pattern of a Report Publication Announcement rather than the report itself.
2026-04-10 English
H股公告-董事会会议通告
Regulatory Filings Classification · 95% confidence The document is a notice of a board meeting scheduled to consider and approve the company's quarterly results for the period ending March 31, 2026. It is a short announcement about the timing and agenda of the board meeting, not the actual quarterly report or financial statements. The document length is only 573 characters, indicating it is a brief notice rather than a full report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about an upcoming board meeting and financial results release, rather than the Interim/Quarterly Report (IR) itself.
2026-04-09 Chinese
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 65% confidence The document is a brief notice of a forthcoming Board meeting to approve and publish quarterly results. It does not itself contain results, executive changes, or proxy materials, nor is it a financial report or presentation. There is no change of directors, dividend announcement, or detailed report. As it does not fit any specific category, it should be classified as a general regulatory announcement – the fallback category (RNS).
2026-04-09 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.